Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 6:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Next Generation Sequencing (NGS) Clear all
Not listed No phase listed Observational

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

NCT03724097
View directory record Official record
Conditions
Cancer
Interventions
RNA sequencing, Transcriptome analysis, target drug with the score above 0,1, target drug with the score equal or below 0,1, non-target drug, palliative care
Other · Drug
Lead sponsor
OmicsWay Corp.
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Walnut, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Sep 14, 2026, 6:02 AM EDT
Recruiting Not applicable Interventional

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

NCT06896162
View directory record Official record
Conditions
Solid Tumor Malignancies, Metastatic Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Bladder Cancer
Interventions
Expert Review, Blood or tissue samples collection., The Precision Oncology Navigation
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Active, not recruiting Not applicable Interventional

Liquid Biopsy Based NGS in Newly Diagnosed NSCLC

NCT05853887
View directory record Official record
Conditions
Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung
Interventions
iNUDGE
Behavioral
Lead sponsor
Charu Aggarwal
Other
Eligibility
Not listed
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Cherry Hill, New Jersey • Plainsboro, New Jersey • Sewell, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Recruiting No phase listed Observational

Familial Investigations of Childhood Cancer Predisposition

NCT03050268
View directory record Official record
Conditions
Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

NCT05275673
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer, Squamous Non-Small Cell Neoplasm of Lung, NFE2L2 Gene Mutation
Interventions
sapanisertib
Drug
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
Davis, California • Santa Rosa, California • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 14, 2026, 6:02 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation

NCT06146920
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer
Interventions
Evaluation of ctDNA using the F1T after 1 year of immunotherapy
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

NCT02899793
View directory record Official record
Conditions
Recurrent Endometrial Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 14, 2026, 6:02 AM EDT
Not listed No phase listed Observational

NGS for Spine Surgery Patients

NCT05013203
View directory record Official record
Conditions
Spine Infection
Interventions
Tissue culture, Next Generation Sequencing
Diagnostic Test
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
450 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 14, 2026, 6:02 AM EDT
Not listed No phase listed Observational

NGS for Non-unions

NCT03937310
View directory record Official record
Conditions
Nonunion of Fracture
Interventions
Next-generation sequencing of swabs collected during surgery
Diagnostic Test
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Sep 14, 2026, 6:02 AM EDT
Recruiting No phase listed Observational

Tempus Small Cell Lung Cancer Observational Study (Sculptor)

NCT05257551
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Los Alamitos, California • Aurora, Colorado • Peoria, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Not listed Not applicable Interventional

NGS vs Culture Outcomes for Treatment of PJI

NCT05247281
View directory record Official record
Conditions
Prosthetic Joint Infection
Interventions
Culture-based treatment, Next Generation Sequencing (NGS) with Culture
Diagnostic Test
Lead sponsor
Center for Innovation and Research Organization
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Weston, Florida • Lebanon, New Hampshire + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 14, 2026, 6:02 AM EDT
Recruiting Not applicable Interventional

Physician- and Patient-based Barriers to NGS Testing

NCT07209176
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Provider-level and patient education at end of study, Provider-level and patient-level
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Not applicable Interventional Results available

Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma

NCT04452292
View directory record Official record
Conditions
Large-Cell Neuroendocrine Carcinoma
Interventions
Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma, Treatment for Small Cell Lung Cancer
Other
Lead sponsor
Charles Kunos
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 14, 2026, 6:02 AM EDT
Completed No phase listed Observational

Genetic Study of Familial Acute Lymphoblastic Leukemia

NCT03067584
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 14, 2026, 6:02 AM EDT
Recruiting No phase listed Observational

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

NCT07154823
View directory record Official record
Conditions
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
Interventions
None - Observational Study
Other
Lead sponsor
Tempus AI
Industry
Eligibility
0 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
10
States / cities
Iowa City, Iowa • Bethesda, Maryland • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Completed No phase listed Observational

Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers

NCT02808494
View directory record Official record
Conditions
Preeclampsia
Interventions
Not listed
Lead sponsor
Illumina, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Newark, Delaware • Boston, Massachusetts • New Brunswick, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 14, 2026, 6:02 AM EDT
Completed No phase listed Observational Results available

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance

NCT03833934
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 14, 2026, 6:02 AM EDT
Not listed Not applicable Interventional

Assessment of Urinary Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) Technology in the Evaluation and Management of Females With Chronic Bladder Pain and Cystitis-like Symptoms

NCT05276466
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Polymerase Chain Reaction and Next-Generation DNA Sequencing
Diagnostic Test
Lead sponsor
MicroGenDX
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 14, 2026, 6:02 AM EDT
Terminated Phase 2 Interventional

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

NCT04265534
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Interventions
Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Folic acid 400 -1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg
Drug · Biological · Dietary Supplement
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 14, 2026, 6:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions
rezatapopt, pembrolizumab
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Completed No phase listed Observational

FoundationOne™ Test Registry Study

NCT01851213
View directory record Official record
Conditions
Cancer, Neoplasm Metastasis, Tumor
Interventions
Not listed
Lead sponsor
Foundation Medicine
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

NCT05199584
View directory record Official record
Conditions
Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions
ENV-101 (taladegib)
Drug
Lead sponsor
Endeavor Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Not yet recruiting Phase 3 Interventional

Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation:

NCT07458230
View directory record Official record
Conditions
Next Generation Sequencing (NGS), Surgical Site Infection (SSI), Fracture Fixation
Interventions
NGS diagnostic findings
Diagnostic Test
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 84 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
18
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Recruiting No phase listed Observational

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

NCT05234177
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
20
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Bethesda, Maryland + 14 more
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 14, 2026, 6:02 AM EDT